NCT06973785 Non-Narcotic Pain Control After ACL Reconstruction
| NCT ID | NCT06973785 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | The Cleveland Clinic |
| Condition | ACL - Anterior Cruciate Ligament Rupture |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-07-15 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 30 participants in total. It began in 2025-07-15 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a double-blind randomized controlled trial of standard of care therapy, either oral ketorolac (experimental group) or oral oxycodone (control group) to demonstrate efficacy in reducing the percentage of narcotic doses taken and documenting the number of patients with no exposure to any narcotics (take zero oxycodone) after undergoing primary knee ACL reconstruction outpatient surgery.
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 15-55 years * Primary Autograft ACL surgery * Ability to take oral medication and willingness to patriciate in a virtual 1 and 2 week follow-up pill counts Exclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for t the duration of the study * Male or female, aged 15-55 years * Primary Autograft ACL surgery * Ability to take oral medication and willingness to patriciate in a virtual 1 and 2 week follow-up pill counts
Contact & Investigator
Kurt P Spindler, MD
PRINCIPAL INVESTIGATOR
The Cleveland Clinic
Frequently Asked Questions
Who can join the NCT06973785 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 55 Years, studying ACL - Anterior Cruciate Ligament Rupture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06973785 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 30 participants.
Is NCT06973785 currently recruiting?
Yes, NCT06973785 is actively recruiting participants. Contact the research team at baldwij3@ccf.org for enrollment information.
Where is the NCT06973785 trial being conducted?
This trial is being conducted at Coral Springs, United States, Garfield, United States, Strongsville, United States.
Who is sponsoring the NCT06973785 clinical trial?
NCT06973785 is sponsored by The Cleveland Clinic. The principal investigator is Kurt P Spindler, MD at The Cleveland Clinic. The trial plans to enroll 30 participants.